Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0L2ZY
|
||||
Former ID |
DNCL002239
|
||||
Drug Name |
X-82
|
||||
Indication | Advanced solid tumor; Macular degeneration [ICD9: 140-199, 362.5; ICD10:C00-C75, C7A, C7B, H35.3] | Phase 1 | [1] | ||
Company |
Tyrogenex West Palm Beach
|
||||
Target and Pathway | |||||
Target(s) | Platelet-derived growth factor receptor | Target Info | Modulator | [2] | |
Vascular endothelial growth factor receptor 1 | Target Info | Modulator | [2] | ||
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
HIF-1 signaling pathway | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
Focal adhesion | |||||
Transcriptional misregulation in cancer | |||||
Rheumatoid arthritis | |||||
Pathway Interaction Database | Glypican 1 network | ||||
HIF-2-alpha transcription factor network | |||||
S1P3 pathway | |||||
VEGF and VEGFR signaling network | |||||
VEGFR1 specific signals | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
Reactome | Neurophilin interactions with VEGF and VEGFR | ||||
VEGF binds to VEGFR leading to receptor dimerization | |||||
WikiPathways | Focal Adhesion | ||||
Signaling by VEGF | |||||
Angiogenesis | |||||
References | |||||
REF 1 | Clinical pipeline report, company report or official report of Tyrogenex. | ||||
REF 2 | National Cancer Institute Drug Dictionary (drug id 695817). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.